Toward precision adjuvant immunotherapy in high-risk clear cell renal cell carcinoma: integrating plasma multiomics with PD-1 blockade
Despite curative-intent nephrectomy, approximately one-third of patients with localized clear cell renal cell carcinoma (ccRCC) eventually experience disease recurrence due to occult minimal residual disease. Although adjuvant immune checkpoint blocka…